Exhibit 99.1

                  ILLUMINA HOLDS ANNUAL MEETING OF STOCKHOLDERS


SAN DIEGO, CALIFORNIA, June 29, 2005 -- Illumina, Inc. (NASDAQ: ILMN) today
announced that the Company held its Annual Meeting of Stockholders on Tuesday,
June 28, 2005, at Illumina's principal executive office in San Diego, CA, as
scheduled. A quorum of stockholders was present in person or by proxy. All
proposals submitted to the Company's stockholders were approved, including the
reelection of two directors to the Board of Directors for three-year terms, the
ratification of Ernst & Young LLP as the Company's independent auditors for the
fiscal year ending January 1, 2006, and the adoption of the Company's 2005 Stock
and Incentive Plan.

The directors reelected to serve until the Company's 2008 Annual Meeting
are Daniel M. Bradbury, Chief Operating Officer of Amylin Pharmaceuticals, Inc.,
and John R. Stuelpnagel D.V.M., Senior Vice President and Chief Operating
Officer of Illumina.

ABOUT ILLUMINA

Illumina (www.illumina.com) is developing next-generation tools that permit
large-scale analysis of genetic variation and function. The Company's
proprietary BeadArray(TM) technology -- now used in leading genome centers
around the world -- provides the throughput, cost effectiveness and flexibility
to enable researchers in the life sciences and pharmaceutical industries to
perform the billions of tests necessary to extract medically valuable
information from advances in genomics and proteomics. This information will help
pave the way to personalized medicine.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995: this release may contain forward-looking statements that involve risks and
uncertainties. Among the important factors that could cause actual results to
differ materially from those in any forward-looking statements are the costs and
outcome of Illumina's litigation with Affymetrix, Illumina's ability to further
develop and commercialize its Infinium assay and BeadArray(TM) platform
technologies, to deploy new gene expression and genotyping products and
applications for its platform technology, to further scale oligo synthesis
output and technology to satisfy market demand deriving from the Company's
collaboration with Invitrogen, to scale, integrate and commercialize the CyVera
technology, to manufacture robust Sentrix(R) arrays and Oligator(R)
oligonucleotides, and other factors detailed in the Company's filings with the
Securities and





Exchange Commission including its recent filings on Forms 10-K and 10-Q or in
information disclosed in public conference calls, the date and time of which are
released beforehand. Illumina disclaims any intent or obligation to update these
forward-looking statements beyond the date of this release.


                                      # # #

Contacts:  Jay Flatley                       William Craumer
           President & CEO                   Director, Corporate Communications
           1.858.202.4501                    1.858.202.4667
           jflatley@illumina.com             bcraumer@illumina.com